期刊
MOVEMENT DISORDERS
卷 34, 期 2, 页码 167-179出版社
WILEY
DOI: 10.1002/mds.27607
关键词
alpha-synuclein; dopamine; oligomers; Parkinson's disease
资金
- NHLBI NIH HHS [R01 HL054926] Funding Source: Medline
- NIA NIH HHS [R01 AG013966] Funding Source: Medline
- NICHD NIH HHS [U54 HD086984] Funding Source: Medline
- NIEHS NIH HHS [P30 ES013508] Funding Source: Medline
- NIGMS NIH HHS [DP1 GM119167, T32 GM008076] Funding Source: Medline
Parkinson's disease (PD) is primarily a movement disorder driven by the loss of dopamine-producing neurons in the substantia nigra (SN). Early identification of the oxidative properties of dopamine implicated it as a potential source of oxidative stress in PD, yet few studies have investigated dopamine neurotoxicity in vivo. The discovery of PD-causing mutations in alpha-synuclein and the presence of aggregated alpha-synuclein in the hallmark Lewy body pathology of PD revealed another important player. Despite extensive efforts, the precise role of alpha-synuclein aggregation in neurodegeneration remains unclear. We recently manipulated both dopamine levels and alpha-synuclein expression in aged mice and found that only the combination of these 2 factors caused progressive neurodegeneration of the SN and an associated motor deficit. Dopamine modified alpha-synuclein aggregation in the SN, resulting in greater abundance of alpha-synuclein oligomers and unique dopamine-induced oligomeric conformations. Furthermore, disruption of the dopamine-alpha-synuclein interaction rescued dopaminergic neurons from degeneration in transgenic Caenorhabditis elegans models. In this Perspective, we discuss these findings in the context of known alpha-synuclein and dopamine biology, review the evidence for alpha-synuclein oligomer toxicity and potential mechanisms, and discuss therapeutic implications. (c) 2019 International Parkinson and Movement Disorder Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据